The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection.Golden, CO, Feb. 10, 2025 (GLOBE ...

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

According to research by nova one advisor, the global cell and gene therapy market size was valued at $18.13 billion in 2023 ...

PHC Corporation and CCRM have signed a Master Collaboration Agreement to collaborate on developing primary T-cell expansion ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

4, 2025 — Research has shown that a potential new targeted therapy ... stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, ...